Results of Operations and Financial Condition. The unaudited interim condensed consolidated financial statements of Korsana as of and for the six months ended June 30, 2026 and the related notes thereto are attached hereto as Exhibit 99.2 and are incorporated herein by reference. Korsana’s Management’s Discussion and Analysis of Financial Condition and Results of Operations as of and for the six months ended June 30, 2026 is attached hereto as Exhibit 99.3 and is incorporated herein by refere…

Entry into a Material Definitive Agreement. Indemnification Agreements On September 8, 2026, the Company entered into indemnification agreements with each of its directors and executive officers (collectively, the “ Indemnitees ,” and such agreements, the “ Indemnification Agreements ”), which replaced and superseded any previous indemnification agreements between the Company and each such individual. The Indemnification Agreements provide for certain indemnification and advancement of expens…

Changes in Control of the Registrant. The information set forth in the “ Introductory Note ” regarding the Merger above, the information set forth in

Material Modification to Rights of Security Holders. Cyclerion held the Annual Meeting on August 26, 2026. At the Annual Meeting, Cyclerion’s shareholders approved, among other matters, articles of amendment to the Articles to (i) increase the number of authorized shares of Cyclerion common stock from 400,000,000 shares to 700,000,000 shares (the “ Authorized Share Increase ”), and (ii) effect the Reverse Stock Split, in each case as described in the Proxy Statement/Prospectus. Following the…

Unregistered Sales of Equity Securities. To the extent required by this Item, the information included in

CEO — Regina M. Graul: The CEO and CFO resigned in connection with a merger closing, which is an orderly succession event rather than a sudden loss of leadership.

by reference. All of the proposals included in the Proxy Statement/Prospectus were approved by Cyclerion shareholders at the annual meeting of shareholders held on August 26, 2026 (the “ Annual Meeting ”) other than (i) the proposal to approve the redomestication of Cyclerion from the Commonwealth of Massachusetts to the Cayman Islands and (ii) the proposal to adjourn the Annual Meeting, which was not presented to the shareholders. In connection with the consummation of the Merger, on the Clo…

Other Events. At the Shareholder Meeting on August 26, 2026, Cyclerion’s shareholders approved the Reverse Stock Split Proposal. Following this approval, the Cyclerion Board approved the reverse stock split of Cyclerion’s issued and outstanding common stock at a final ratio, agreed to by Korsana, of 1-for-7 shares of Cyclerion common stock (the “Reverse Stock Split”). Prior to the closing of the Merger, Cyclerion will file articles of amendment to the Cyclerion Articles with the Secretary of…

Other Events. On August 25, 2026, the board of directors of Cyclerion Therapeutics, Inc. (the “Company”) fixed the close of business on September 4, 2026 as the record date for the Company’s previously announced distribution (the “CVR Distribution”) of contingent value rights (“CVRs”) to holders of record of the Company’s common stock and the Company’s Series A Preferred Stock, in connection with the Company’s planned merger (the “Merger”) with Korsana Biosciences, Inc. (“Korsana”). Forward-L…

Regulation FD Disclosure. On April 1, 2026, Cyclerion and Korsana issued a joint press release announcing the entry into the Merger Agreement. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference, except that the information contained on the websites referenced in the press release is not incorporated herein by reference. Furnished as Exhibit 99.2 hereto and incorporated herein by reference is the investor presentation that wil…

Changes in Control of Registrant. To the extent required by this Item, the information included in

Entry into a Material Definitive Agreement. Merger Agreement On April 1, 2026, Cyclerion Therapeutics, Inc., a Massachusetts corporation (“ Cyclerion ”), Cariboos Merger Sub Corp., a Delaware corporation and a wholly owned subsidiary of Cyclerion (“ First Merger Sub ”), Cariboos Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of Cyclerion (“ Second Merger Sub ” and, together with First Merger Sub, “ Merger Sub ”), and Korsana Biosciences, Inc., a Delaware…

The filing appears to be a placeholder or incomplete, not detailing any specific management change.

Entry into a Material Definitive Agreement. On January 3, 2026, Cyclerion Therapeutics, Inc. (the “Company”) and the Medsteer, SAS (“Medsteer”) entered into a Collaboration and Option Agreement (the “Collaboration Agreement”) pursuant to which Medsteer granted to the Company (i) a non-exclusive, worldwide, royalty-free, sublicensable license of certain of Medsteer’s technology, software and intellectual property to develop an anesthetic delivery system with Medsteer and (ii) an exclusive opti…

Regulation FD Disclosure On January 5, 2026, the Company issued a press release announcing its entry into the Collaboration Agreement and providing an update on the development of CYC-126, its lead product candidate. In addition, the Company has prepared an investor presentation with respect to the License Agreement and update on CYC-126. A copy of the press release and investor presentation are attached to this Current Report on Form 8-K as Exhibit 99.1 and Exhibit 99.2, respectively, and in…

Other Events On December 1, 2025, Akebia Therapeutics, Inc. (“Akebia”) publicly announced that it has recently initiated Phase 2 clinical trials for the treatment of focal segmental glomerulosclerosis (“FSGS”) using Praliciguat, an oral soluble guanylate cyclase licensed to Akebia by Cyclerion Therapeutics, Inc. (Cyclerion”). Pursuant to the terms of Amendment #1 to the License Agreement by and between Akebia and Cyclerion, upon initiation (defined as first patient dosed) of a Phase 2 clinica…

Entry into a Material Definitive Agreement. On September 19, 2025, Cyclerion Therapeutics, Inc. (the “Company”) and the Massachusetts Institute of Technology (“MIT”) entered into a Patent License Agreement (the “License Agreement”) pursuant to which MIT granted to the Company an exclusive worldwide license to develop and commercialize products using certain technology for the treatment of neuropsychiatric disorders, such as depression, in humans. Under the terms of the License Agreement, the…

Entry into a Material Definitive Agreement. On May 7, 2025, Cyclerion Therapeutics, Inc. (the “Company”) and Guggenheim Securities, LLC (“Guggenheim Securities”) entered into a Sales Agreement (the “Sales Agreement”), pursuant to which the Company may offer and sell shares of common stock, no par value per share (the “Shares”), having an aggregate offering price of up to $20,000,000 from time to time through or to Guggenheim Securities, acting as the Company’s agent, subject to the applicatio…

Unregistered Sales of Equity Securities. The information contained in

Entry into a Material Definitive Agreement. Stock Purchase Agreement On March 21, 2025, Cyclerion Therapeutics, Inc. (the “ Company ”) entered into a Stock Purchase Agreement (the “ Purchase Agreement ”) with the investors named therein, including Peter Hecht and Michael Higgins, who serve as members of the Company’s Board of Directors (each, an “ Investor ” and collectively, the “ Investors ”) for the private placement of 499,998 shares (the “ Shares ”) of the Company’s common stock, no par…

ENTRY INTO A MATERIAL AGREEMENT On December 13, 2024, Cyclerion Therapeutics, Inc. (the “Company” or “Cyclerion””) and Akebia Therapeutics, Inc. (“Akebia”) entered into Amendment #1 to License Agreement (the “Amendment”) to the original License Agreement between the parties dated June 3, 2021 (the “2021 License Agreement”). Under the terms of the Amendment, Akebia has agreed to pay to the Company (i) $1,250,000 before December 31, 2024, and (ii) $500,000 on or before September 30, 2025. In ad…

President — Regina Graul Ph.D.: Regina Graul was promoted to President, replacing Peter Hecht who resigned but will continue as a consultant and board member.

Director — Michael Higgins, Dina Katabi, Ph.D.: The Board of Directors increased its size and elected two new independent directors.

Director — Ole Isacson, M.D., Ph.D.: Dr. Ole Isacson resigned as a director of the company.

Chief Financial Officer — Anjeza Gjino: Ms. Gjino resigned from her position as Chief Financial Officer with a severance package.